AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03034941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg twice per day per os for 12 weeks
Study NCT03034941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide + metformin
Description: In the COMBI group the initial dose of metformin was 500 mg for at least 2 wk and gradually increased to a final dose of 1000 mg twice per day. Liraglutide 1.2 mg once per day s.c. was added after first two weeks of monotherapy with metformin.
Study NCT03455387 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: sampling of the serum marker sFlt1 and PlGF
Description: sampling of the serum markers sFlt1 and PlGF , every 3 days,until delivery
Study NCT01818349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isokinetic lower-limb training
Description: concentric training of the affected plantarflexors, hip flexors and hip extensors
Study NCT00711386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT03501147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: 15 minutes of resistance training during work every day
Study NCT02095054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Dose Escalation Group Starting Dose of Regorafenib: 80 mg by mouth once a day for 21 days (5 days on and 2 days off) in a 28 days cycle.~Dose Expansion Group Starting Dose of Regorafenib : MTD from Dose Escalation Group.
Study NCT02095054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Dose Escalation Group Starting Dose of Cetuximab: 200 mg/m2 initial dose, then 150 mg/m2 by vein over about 1-2 hours on Days 1, 8, 15, and 22 of each 28 day cycle.~Dose Expansion Group Starting Dose of Cetuximab: MTD from Dose Escalation Group.
Study NCT02095054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Symptom questionnaire completed at each study visit.
Study NCT01004341 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Family-based behavioral weight control intervention
Description: Standard behavioral weight control program for children ages 8-12 years old and their parents in a family-based intervention.
Study NCT05385640 — intervention group
Intervention type: OTHER
Intervention: NO intervention
Description: NO intervention
Study NCT03598595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT03598595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT03598595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Given PO
Study NCT00836576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril HCl 40 mg Tablets
Description: 1 x 40 mg, single-dose fasting
Study NCT00836576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lotensin® 40 mg Tablets
Description: 1 x 40 mg, single-dose fasting
Study NCT01880632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Patients will be given the perioperative chemotherapy as below once recruited:~Capecitabine ：500 mg tablets（Roche） Oxaliplatin：50mg/10ml（according to daily practice in each center）~Schedule of Oxaliplatin plus capecitabine (XELOX) will be as follow:~Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1\~14 every 3 weeks(treatment for 2 weeks and rest 1 week) Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks
Study NCT01959672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4-Dimensional Computed Tomography
Description: Correlative studies
Study NCT01959672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT01959672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT01959672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01959672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT01959672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir Mesylate
Description: Given PO
Study NCT01959672 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oregovomab
Description: Given IV
Study NCT01959672 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT01959672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection
Study NCT02000362 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cells
Study NCT02374385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPSC-1001 (VSVΔG-ZEBOV)
Description: Ebola vaccine candidate
Study NCT01818349 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: isokinetic upper-limb training
Description: concentric training of the affected wrist extensors, elbow flexors and shoulder flexors
Study NCT02568904 — intervention group
Intervention type: OTHER
Intervention: Alcohol
Description: every participant will drink vodka at a dose of 2ml/kg bodyweight
Study NCT02568904 — intervention group
Intervention type: OTHER
Intervention: Glucose
Description: oral Glucose tolerance test
Study NCT02568904 — intervention group
Intervention type: OTHER
Intervention: Fructose
Description: oral fructose tolerance test
Study NCT02568904 — intervention group
Intervention type: OTHER
Intervention: vehicle
Description: control (water)
Study NCT03633331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study NCT03633331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study NCT03633331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM
Study NCT03633331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03633331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03146312 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MVM/phytochemical supplement
Description: Consumption of an MVM/phytochemical supplement for 4 weeks
Study NCT03146312 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Consumption of a placebo tablet identical in size, shape and color to the treatment tablet
Study NCT02090543 — intervention group
Intervention type: DRUG
Intervention: Phenprocoumon (Marcumar)
Description: common use, no requirements (real life situation)
Study NCT02090543 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY-59 7939)
Description: common use, no requirements (real life situation)
Study NCT01009294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Oral powder
Study NCT01009294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronic Corticosteroid Therapy
Description: Enrollment was stratified to ensure evaluation of approximately half of the participants were receiving chronic corticosteroid therapy and approximately half of participants were not receiving chronic corticosteroid therapy. Therefore, 3 out of 6 participants were receiving chronic corticosteriod therapy. For the participants receiving chronic corticosteriod therapy, a stable corticosteriod regimen was to be maintained during the study.
Study NCT04655625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group A (AG0302-COVID19)
Description: 2 mg of AG0302-COVID19 twice at 2-week intervals
Study NCT04655625 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Group A (Placebo)
Description: Placebo twice at 2-week intervals
Study NCT04655625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B (AG0302-COVID19)
Description: 2 mg of AG0302-COVID19 twice at 4-week intervals
Study NCT04655625 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Group B (Placebo)
Description: Placebo twice at 4-week intervals
Study NCT03671122 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac imaging in the PREFERS and CABG PREFERS cohorts
Description: performed at baseline and after 1 year
Study NCT03671122 — intervention group
Intervention type: OTHER
Intervention: Biomarker analysis in the PREFERS and CABG PREFERS chorts
Description: blood samples will be taken for biomarker analysis at baseline and after 1 year
Study NCT03671122 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac biopsies in the CABG PREFERS cohort
Description: myocardial biopsies from the right trium the left and right ventricles will be taken during elective CABG
Study NCT04537442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM21 CAR-T cells
Description: IM21 CAR-T cells~Drug: Fludarabine~Two days before cell infusion, all patients will be treated with fludarabine for 3 days~Drug: Cyclophosphamide~Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days~Other Names:~Fludarabine Cyclophosphamide
Study NCT00373074 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Blood Patch
Description: Use 15 cc of blood
Study NCT00373074 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Blood Patch
Description: Inject 20 cc of blood into epidural space
Study NCT00373074 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Blood Patch
Description: Inject 30 cc of autologous blood
Study NCT00587223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apligraf
Description: Up to 3 applications: Day 0, Month 1, Month 2.
Study NCT00587223 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard dressing regimen
Description: Dressing regimen will be comprised of a primary nonadherent dressing, nonstick gauze and standard dressing retainer
Study NCT02511210 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: regional anesthesia
Description: preoperative anxiety
Study NCT02511210 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: preoperative anxiety
Study NCT04205552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/ML Intravenous Solution
Description: Neoadjuvant 2 cycles, every two weeks (q2w) Nivolumab 240 mg i.v. over 30 min
Study NCT00614393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan hydrochloride
Description: IV infusion
Study NCT00614393 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: IV infusion
Study NCT00614393 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: IV infusion
Study NCT00614393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: IV infusion
Study NCT03071744 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lazanda
Description: Lazanda is supplied in glass bottles, containing 8 sprays of 100 mcL containing 100 mcg/100 mcL or 400 mcg/100 mcL concentration solution.
Study NCT03639389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Spinal anesthesia with a combination of bupivacaine and fentanyl or sufentanil
Study NCT02374385 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study NCT03388671 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAB Block
Description: patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided TAB Block
Study NCT03388671 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Psoas Block
Description: patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided Psoas Block
Study NCT03388671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided Psoas Block or TAB block
Study NCT02646124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen 500mg by mouth two times a day, #20
Study NCT02646124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500mg by mouth two times a day, #20
Study NCT02646124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 28 placebo capsules
Study NCT02646124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: Diazepam 5mg capsules, 1-2 tabs by mouth two times a day, #28
Study NCT03639389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesics
Description: Combination of paracetamol + non-steroidal anti-inflammatory drug + morphine to all patients
Study NCT01588509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection
Study NCT04075578 — intervention group
Intervention type: DRUG
Intervention: OnabotulinumtoxinA / Botox®, Allergan Ltd, Irvine, CA, United-States
Description: Botox® intradetrusor injections, with a rigid cystoscope, under local anaesthesia performed by Lidocaïne 2% diluted in 30ml of bicarbonate 14‰. 20 injections of 0,5ml each will be heterogeneously administrated into the bladder wall, sparing the trigone
Study NCT02561585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 124249
Study NCT02561585 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study NCT03465839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education for improving handovers quality
Description: Specific education on the importance of handovers quality will be provided. The educational session will last 4 hours. The program will be divided into the following sections: 1) a structured survey on the perception of the participants on the handovers importance; 2) Key theoretical concepts on the relevance of handovers with case studies of errors related to this critical moment; 3) showing movie clips of nursing handovers to critically interpret the clips by the participants; 4) presentation of the SBAR method recommended by WHO; 5) general presentation of the nursing delivery assessment project of the Valduce Hospital.
Study NCT03465839 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education for improving handovers quality
Description: Specific education on the importance of handovers quality will be provided. The educational session will last 4 hours. The program will be divided into the following sections: 1) a structured survey on the perception of the participants on the handovers importance; 2) Key theoretical concepts on the relevance of handovers with case studies of errors related to this critical moment; 3) showing movie clips of nursing handovers to critically interpret the clips by the participants; 4) presentation of the SBAR method recommended by WHO; 5) general presentation of the nursing delivery assessment project of the Valduce Hospital.
Study NCT03465839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education for improving bedside handovers
Description: In addition to the education for improving handovers quality, the following intervention will be implemented for nurses assigned to the study department. The course will be supplemented by a section of the duration of an hour, containing 1) information on the principles underlying bedside handovers; 2) how to handle information in front of the patient and on his / her direct involvement; 3) role-playing of the bedside handover will be performed, assigning the roles of nurse and patient among the participants to bring out impressions linked to the functions.
Study NCT00764777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iliac stenting
Description: Absolute Pro (Abbott Vascular) or Omnilink Elite (Abbott Vascular) stents
Study NCT01367145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OMACOR
Description: 4 capsules OMACOR 1g per day
Study NCT01367145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules placebo per day
Study NCT02503527 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diben 1.5 kcal HP
Description: Continuous (24h) application according to a standardized enteral feeding protocol via nasogastric tube or percutaneous endoscopic gastrostomy (PEG); pump-assisted application (Charriére (CH) > 8), duration according to patient's tolerance and requirements for a maximum of 5 days. Dosage: 21 - 24 kcal/kg body weight/day (corresponding to 14 to 16 ml/kg body weight/day).
Study NCT02503527 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fresubin HP Energy Fibre (1.5 kcal)
Description: Continuous (24h) application according to a standardized enteral feeding protocol via nasogastric tube or percutaneous endoscopic gastrostomy (PEG); pump-assisted application (Charriére (CH) > 8), duration according to patient's tolerance and requirements for a maximum of 5 days. Dosage: 21 - 24 kcal/kg body weight/day (corresponding to 14 to 16 ml/kg body weight/day).
Study NCT03201523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Socio-ecologial, community-based intervention
Description: Intervention components will include a health newsletter, health workshops, community evening/health project registration, lay leader training, neighborhood exercise groups, community walking programs with pedometers, healthy cooking contest, and school health promotion activities.
Study NCT04414228 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: M-Entropy guidance of anesthesia depth
Description: In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the response and state entropy values between 40 and 60 from the start of anesthesia to the end of surgery. In the control group, dosage of volatile anesthetics will be titrated according to clinical judgment.
Study NCT04414228 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProAQT in guiding goal-directed hemodynamic therapy
Description: If stroke volume variation is ≥ 10%, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is \< 10%. If mean arterial pressure is \< 70 mmHg and/or cardiac index \< 2.5 l·min-1·m-2 despite the stroke volume variation of \< 10% following fluid challenge, single or consecutive boluses of ephedrine 4 mg and/or continuous intravenous infusion of norepinephrine 2-10 μg·min-1 will be administered.
Study NCT05474365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stepwise training
Description: The protocol of stepwise training is mentioned in Detailed description in Study Description.
Study NCT05401734 — intervention group
Intervention type: DEVICE
Intervention: Observation and follow up measurement
Description: The measured variables include:~Questionnaires~* Health related quality of life (Health Related Quality of Life Questionnaire)~* Physical activity level (Physical Activity Scale for Persons with Impairments and Disabilities)~* Walking ability (Walking Index for Spinal Cord Injury)~* Independence in activities of daily living (SCIM III Questionnaire)~* Pain (International SCI Pain Basic Data Set)~* Resilience (Resilience Scale)~* Bowel and bladder function (Neurogenic Bowel Dysfunction score, International Consultation on Incontinence Modular Questionnaire - Lower Urinary Tract Symptoms)~Measurements:~* Muscular strength and joint ROM (Manual Muscle Testing)~* Spasticity (Modified Ashworth Scale)~* Walking parameters (walking time, crutch position, forward and lateral center of gravity shift, step length and height, swing phase, walking speed)~* Cardiovascular response (blood pressure, heart frequency, blood lactate concentration and Borg RPE score)
Study NCT02937870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Product 1
Description: Test adhesive 1 with a thin nozzle
Study NCT02937870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Product 2
Description: Test adhesive 2 with a thin nozzle
Study NCT02937870 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reference Product
Description: Adhesive Cream
Study NCT02937870 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Negative Control
Description: No adhesive
Study NCT03789565 — intervention group
Intervention type: OTHER
Intervention: Biomarker test
Description: Diagnostic biomarker study
Study NCT04503174 — intervention group
Intervention type: DEVICE
Intervention: t:slim X2 pump with Control-IQ technology
Description: Real-world use
Study NCT04289870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trillium™
Description: Trillium™ Stent Graft for Functional Tricuspid Valve Replacement
Study NCT01515592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: One daily subcutaneous dose for 5 weeks. Dose is weekly incremented with 5 mcg/kg
Study NCT01515592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg the third week, and finally 20 mcg for 2 weeks
Study NCT01515592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg for 3 weeks